2010+

The IGES Institute is growing nationally and internationally: how can the globally growing importance of health economic assessments be appropriately considered?

In 2011, for the first time in the history of German health policy, prices for medicinal products can no longer be freely set by pharmaceutical companies, but are linked to the degree of additional benefits the respective drugs have. With this, health economics assessments and cost-benefit analyses have become obligatory for the SHI market. In order to meet the growing demand in this field, the IGES Institute is expanding its range of services and strengthening its national presence with an office in Nuremberg, where a team of experts “Health Economics & Outcomes Research (HEOR)” has been working since 2012.


With the acquisition of the Switzerland-based healthcare consulting institute HealthEcon AG (Basel) in 2012, the IGES Group has started to transfer its successful concept to other European countries—marking a starting point for growth beyond national borders.
IGES is expanding its services with interdisciplinary consulting in order to meet clients’ needs more specifically with expertise.